Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Imidazo[2,1-a]isoquinoline-2-carbohydrazide is a synthetic small molecule belonging to the isoquinoline derivative class. It has the molecular formula C12H10N4O and a molecular weight of approximately 226.23 g/mol. The compound is primarily of research interest and is classified as experimental; it has not been approved for clinical use in any country and does not have known indications or associated conditions in clinical trials. Compounds within the broader imidazoisoquinoline class have been studied for potential anticancer and anti-inflammatory activities; however, there are no specific data on mechanism of action or therapeutic application for this particular molecule.[1][3][4][5][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on imidazo[2,1-a]isoquinoline-2-carbohydrazide.